302 related articles for article (PubMed ID: 29175157)
1. Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier.
Albright BH; Storey CM; Murlidharan G; Castellanos Rivera RM; Berry GE; Madigan VJ; Asokan A
Mol Ther; 2018 Feb; 26(2):510-523. PubMed ID: 29175157
[TBL] [Abstract][Full Text] [Related]
2. Modulation of Sialic Acid Dependence Influences the Central Nervous System Transduction Profile of Adeno-associated Viruses.
Albright BH; Simon KE; Pillai M; Devlin GW; Asokan A
J Virol; 2019 Jun; 93(11):. PubMed ID: 30894463
[TBL] [Abstract][Full Text] [Related]
3. Context-Specific Function of the Engineered Peptide Domain of PHP.B.
Martino RA; Fluck EC; Murphy J; Wang Q; Hoff H; Pumroy RA; Lee CY; Sims JJ; Roy S; Moiseenkova-Bell VY; Wilson JM
J Virol; 2021 Sep; 95(20):e0116421. PubMed ID: 34346767
[TBL] [Abstract][Full Text] [Related]
4. Comparative Analysis of the Capsid Structures of AAVrh.10, AAVrh.39, and AAV8.
Mietzsch M; Barnes C; Hull JA; Chipman P; Xie J; Bhattacharya N; Sousa D; McKenna R; Gao G; Agbandje-McKenna M
J Virol; 2020 Feb; 94(6):. PubMed ID: 31826994
[TBL] [Abstract][Full Text] [Related]
5. In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy.
Choudhury SR; Fitzpatrick Z; Harris AF; Maitland SA; Ferreira JS; Zhang Y; Ma S; Sharma RB; Gray-Edwards HL; Johnson JA; Johnson AK; Alonso LC; Punzo C; Wagner KR; Maguire CA; Kotin RM; Martin DR; Sena-Esteves M
Mol Ther; 2016 Aug; 24(7):1247-57. PubMed ID: 27117222
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site.
Huang LY; Patel A; Ng R; Miller EB; Halder S; McKenna R; Asokan A; Agbandje-McKenna M
J Virol; 2016 Jun; 90(11):5219-5230. PubMed ID: 26962225
[TBL] [Abstract][Full Text] [Related]
7. The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice.
Hordeaux J; Wang Q; Katz N; Buza EL; Bell P; Wilson JM
Mol Ther; 2018 Mar; 26(3):664-668. PubMed ID: 29428298
[TBL] [Abstract][Full Text] [Related]
8.
Batista AR; King OD; Reardon CP; Davis C; Shankaracharya ; Philip V; Gray-Edwards H; Aronin N; Lutz C; Landers J; Sena-Esteves M
Hum Gene Ther; 2020 Jan; 31(1-2):90-102. PubMed ID: 31696742
[TBL] [Abstract][Full Text] [Related]
9. Widespread transduction of astrocytes and neurons in the mouse central nervous system after systemic delivery of a self-complementary AAV-PHP.B vector.
Rincon MY; de Vin F; Duqué SI; Fripont S; Castaldo SA; Bouhuijzen-Wenger J; Holt MG
Gene Ther; 2018 Apr; 25(2):83-92. PubMed ID: 29523880
[TBL] [Abstract][Full Text] [Related]
10. Challenges in adeno-associated virus-based treatment of central nervous system diseases through systemic injection.
Huang L; Wan J; Wu Y; Tian Y; Yao Y; Yao S; Ji X; Wang S; Su Z; Xu H
Life Sci; 2021 Apr; 270():119142. PubMed ID: 33524419
[TBL] [Abstract][Full Text] [Related]
11. Structure of neurotropic adeno-associated virus AAVrh.8.
Halder S; Van Vliet K; Smith JK; Duong TT; McKenna R; Wilson JM; Agbandje-McKenna M
J Struct Biol; 2015 Oct; 192(1):21-36. PubMed ID: 26334681
[TBL] [Abstract][Full Text] [Related]
12. Intravenous Infusion of AAV for Widespread Gene Delivery to the Nervous System.
Gessler DJ; Tai PWL; Li J; Gao G
Methods Mol Biol; 2019; 1950():143-163. PubMed ID: 30783972
[TBL] [Abstract][Full Text] [Related]
13. Crossing the blood-brain barrier with AAV vectors.
Liu D; Zhu M; Zhang Y; Diao Y
Metab Brain Dis; 2021 Jan; 36(1):45-52. PubMed ID: 33201426
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the relationship of AAV capsid domain swapping to liver transduction efficiency.
Shen X; Storm T; Kay MA
Mol Ther; 2007 Nov; 15(11):1955-62. PubMed ID: 17726459
[TBL] [Abstract][Full Text] [Related]
15. Development of CNS tropic AAV1-like variants with reduced liver-targeting following systemic administration in mice.
Drouyer M; Merjane J; Nazareth D; Knight M; Scott S; Liao SHY; Ginn SL; Zhu E; Alexander IE; Lisowski L
Mol Ther; 2024 Mar; 32(3):818-836. PubMed ID: 38297833
[TBL] [Abstract][Full Text] [Related]
16. A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection.
Yang L; Jiang J; Drouin LM; Agbandje-McKenna M; Chen C; Qiao C; Pu D; Hu X; Wang DZ; Li J; Xiao X
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3946-51. PubMed ID: 19234115
[TBL] [Abstract][Full Text] [Related]
17. Widespread Central Nervous System Gene Transfer and Silencing After Systemic Delivery of Novel AAV-AS Vector.
Choudhury SR; Harris AF; Cabral DJ; Keeler AM; Sapp E; Ferreira JS; Gray-Edwards HL; Johnson JA; Johnson AK; Su Q; Stoica L; DiFiglia M; Aronin N; Martin DR; Gao G; Sena-Esteves M
Mol Ther; 2016 Apr; 24(4):726-35. PubMed ID: 26708003
[TBL] [Abstract][Full Text] [Related]
18. Customized blood-brain barrier shuttle peptide to increase AAV9 vector crossing the BBB and augment transduction in the brain.
Zhang X; Chai Z; Lee Dobbins A; Itano MS; Askew C; Miao Z; Niu H; Samulski RJ; Li C
Biomaterials; 2022 Feb; 281():121340. PubMed ID: 34998171
[TBL] [Abstract][Full Text] [Related]
19. Safe and stable noninvasive focal gene delivery to the mammalian brain following focused ultrasound.
Stavarache MA; Petersen N; Jurgens EM; Milstein ER; Rosenfeld ZB; Ballon DJ; Kaplitt MG
J Neurosurg; 2018 Apr; 130(3):989-998. PubMed ID: 29701544
[TBL] [Abstract][Full Text] [Related]
20. Directed evolution of adeno-associated virus (AAV) as vector for muscle gene therapy.
Yang L; Li J; Xiao X
Methods Mol Biol; 2011; 709():127-39. PubMed ID: 21194025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
